Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia.

Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF.

Blood. 2010 Jul 8;116(1):129-39. doi: 10.1182/blood-2009-12-257253. Epub 2010 Apr 27.

2.

Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo.

Cooper ML, Choi J, Karpova D, Vij K, Ritchey J, Schroeder MA, DiPersio JF.

J Immunol. 2017 May 1;198(9):3746-3754. doi: 10.4049/jimmunol.1502399. Epub 2017 Mar 22.

PMID:
28330901
3.

Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.

Pillai AB, George TI, Dutt S, Strober S.

Blood. 2009 Apr 30;113(18):4458-67. doi: 10.1182/blood-2008-06-165506. Epub 2009 Feb 12.

4.

Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.

Yang J, Fan H, Hao J, Ren Y, Chen L, Li G, Xie R, Yang Y, Qian K, Liu M.

Transfusion. 2012 Jun;52(6):1333-47. doi: 10.1111/j.1537-2995.2011.03448.x. Epub 2011 Nov 21.

PMID:
22098312
5.
6.

Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models.

Duramad O, Laysang A, Li J, Ishii Y, Namikawa R.

Biol Blood Marrow Transplant. 2011 Aug;17(8):1154-68. doi: 10.1016/j.bbmt.2010.11.022. Epub 2010 Dec 8.

7.

CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.

Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR.

J Immunol. 2012 Jul 1;189(1):464-74. doi: 10.4049/jimmunol.1200886. Epub 2012 May 30.

8.

DNA methylation controls Foxp3 gene expression.

Polansky JK, Kretschmer K, Freyer J, Floess S, Garbe A, Baron U, Olek S, Hamann A, von Boehmer H, Huehn J.

Eur J Immunol. 2008 Jun;38(6):1654-63. doi: 10.1002/eji.200838105.

9.

Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses.

Vogtenhuber C, Bucher C, Highfill SL, Koch LK, Goren E, Panoskaltsis-Mortari A, Taylor PA, Farrar MA, Blazar BR.

Blood. 2010 Jul 22;116(3):466-74. doi: 10.1182/blood-2009-11-252825. Epub 2010 May 4.

10.

Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.

Pallandre JR, Brillard E, Créhange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C.

J Immunol. 2007 Dec 1;179(11):7593-604.

11.

Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation.

Singer BD, Mock JR, Aggarwal NR, Garibaldi BT, Sidhaye VK, Florez MA, Chau E, Gibbs KW, Mandke P, Tripathi A, Yegnasubramanian S, King LS, D'Alessio FR.

Am J Respir Cell Mol Biol. 2015 May;52(5):641-52. doi: 10.1165/rcmb.2014-0327OC.

12.

Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice.

Semple K, Yu Y, Wang D, Anasetti C, Yu XZ.

Biol Blood Marrow Transplant. 2011 Mar;17(3):309-18. doi: 10.1016/j.bbmt.2010.12.710. Epub 2011 Jan 9.

13.

Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation.

Cao J, Chen C, Zeng L, Li L, Li Z, Xu K.

Leuk Res. 2010 Oct;34(10):1374-82. doi: 10.1016/j.leukres.2009.11.024. Epub 2009 Dec 16.

PMID:
20018376
14.

Comparative analysis of dendritic cells and anti-CD3/CD28 expanded regulatory T cells for application in transplantation.

Zeng M, Guinet E, Nouri-Shirazi M.

Transpl Immunol. 2009 Dec;22(1-2):82-92. doi: 10.1016/j.trim.2009.07.004. Epub 2009 Jul 25.

PMID:
19635560
15.

Natural killer cells prevent CD28-mediated Foxp3 transcription in CD4+CD25- T lymphocytes.

Brillard E, Pallandre JR, Chalmers D, Ryffel B, Radlovic A, Seilles E, Rohrlich PS, Pivot X, Tiberghien P, Saas P, Borg C.

Exp Hematol. 2007 Mar;35(3):416-25.

PMID:
17309822
16.

Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period.

Inoue T, Ikegame K, Kaida K, Okada M, Yoshihara S, Tamaki H, Fujimori Y, Soma T, Ogawa H.

J Immunol. 2016 Jan 1;196(1):469-83. doi: 10.4049/jimmunol.1402950. Epub 2015 Nov 30.

17.

Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.

Kim BS, Nishikii H, Baker J, Pierini A, Schneidawind D, Pan Y, Beilhack A, Park CG, Negrin RS.

Blood. 2015 Jul 23;126(4):546-57. doi: 10.1182/blood-2015-04-637587. Epub 2015 Jun 10.

18.

Suppression of alloimmunity in mice by regulatory T cells converted with conditioned media.

Teng L, Liu L, Su Y, Yuan X, Li J, Fu Q, Chen S, Wang C.

J Surg Res. 2011 Dec;171(2):797-806. doi: 10.1016/j.jss.2010.03.044. Epub 2010 Apr 15.

PMID:
20538297
19.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.

Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32.

20.

FOXP3 demethylation as a means of identifying quantitative defects in regulatory T cells in acute coronary syndrome.

Lü CX, Xu RD, Cao M, Wang G, Yan FQ, Shang SS, Wu XF, Ruan L, Quan XQ, Zhang CT.

Atherosclerosis. 2013 Jul;229(1):263-70. doi: 10.1016/j.atherosclerosis.2013.05.007. Epub 2013 May 16.

PMID:
23735638

Supplemental Content

Support Center